Pfizer launches early safety trial for new arthritis and lupus drug
NCT ID NCT07235163
First seen Nov 19, 2025 · Last updated May 16, 2026 · Updated 23 times
Summary
This early-stage study tests a new medicine, PF-08065010, in 100 healthy adults aged 18-65 to check its safety and how the body processes it. Participants receive either the drug or a placebo as a shot or IV, with some getting a single dose and others monthly doses for 3 months. The goal is to gather safety data before testing it in people with rheumatoid arthritis or lupus.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.